News

The European Commission has approved Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated…

A professor at the University of Freiburg, in Germany, was awarded the Novo Nordisk Prize for his research into the role of microglia in diseases such as multiple sclerosis (MS) and Alzheimer’s disease, and how they might be used as early warning signs of these disorders. Marco Prinz, MD,…

Lower antibody levels in the bloodstream and younger age are associated with a greater likelihood of infection in people with multiple sclerosis (MS) receiving Ocrevus (ocrelizumab) therapy, a study has found. “Our work adds to the body of literature detailing real-world outcomes in MS patients treated with [Ocrevus] and…

Women with multiple sclerosis (MS) diagnosed with breast cancer are not at a higher risk of dying from cancer than women without the neurodegenerative disorder, according to a Canadian population-based study. However, 10 years after their breast cancer diagnosis, women with MS were 28% more likely to die from any…

The digital therapeutics company MedRhythms is launching a clinical trial to evaluate the safety and efficacy of MR-004, an experimental product that uses rhythmic sounds to improve walking abilities in people with multiple sclerosis (MS). The randomized…

Lower blood levels of vitamin D binding protein, known as VDBP, were observed in newly diagnosed multiple sclerosis (MS) patients in a new study — findings that suggest the protein could potentially act as a biomarker for the neurodegenerative disease. “The…

LIF, a protein with anti-inflammatory and neuroprotective properties, can be successfully delivered to immune cells in the brain using a nanoparticle formulation, and partially reverses induced paralysis in a mouse model of multiple sclerosis (MS), a proof-of-concept study has found. These findings validate LIF-loaded nanoparticles as…

Stop Multiple Sclerosis is the theme of this year’s World Brain Day, taking place July 22 to raise global awareness of multiple sclerosis (MS) through seminars, conferences and other presentations. “Every year, we use World Brain Day to highlight an area of neurology that needs the world’s attention,”…

The National Multiple Sclerosis Society (NMSS) and iRacing are revving up for a special, July 31 motoring event to raise funds for the advocacy group. Called the iRacing 4 Hours at Charlotte Benefiting the National MS Society, the event will stream live at twitch.tv/iracing and marks iRacing’s…

Due to differences in sex chromosomes, certain immune cells cause more severe disease in males than females, according to a new study in a mouse model of multiple sclerosis (MS). The findings could help to explain why biological males with MS tend to have more severe disease. The study,…

MindMaze’s animated ‘games,’ designed to aid in recovering motor and cognitive skills in people with neurological disabilities, such as multiple sclerosis (MS), will now be more widely available to patients worldwide. The brain technology company announced four new partnerships that will enable patients in Latin America, the Middle East,…

Perceptions of a medication can predict treatment adherence and persistence — sticking with the same therapy — in people with multiple sclerosis (MS), a prospective observational study found. The findings were the result of a clinical study (NCT02488343) evaluating the profile of adherence to therapy in patients ages…

Treatment with Mavenclad (clabridine) reduces the frequency of relapses in people with relapsing-remitting multiple sclerosis (RRMS), with benefits appearing to be evident two years after patients stopped taking the treatment, new data suggest. These findings were in the study, “Analysis of frequency and severity of relapses…

The National Institute for Health and Care Excellence (NICE) has maintained its initial draft recommendation and will not recommend that Zeposia (ozanimod) be added to the National Health Service (NHS) of England and Wales. This final decision on the cost effectiveness of the oral therapy means Zeposia will…

B-cell-depleting therapies given to adults with multiple sclerosis (MS) affect the production of antibodies targeting SARS-CoV-2, the virus that causes COVID-19, a study reported. This finding has “consequences” for immunity in this patient group, whether that immunity follows SARS-CoV-2 infection or…

A conversational bot is being developed at the University of Illinois at Urbana-Champaign (UIUC) to promote COVID-19 vaccinations among people with multiple sclerosis (MS) who are hesitant to take the vaccine. The project is meant to provide accessible digital health information about the vaccines to more vulnerable populations…

Therini Bio announced raising $17 million in a financing round to speed the development of an antibody that might treat people with inflammatory conditions, such as multiple sclerosis (MS), associated with damage to blood vessels. These funds will also support work aiming to move this antibody, targeting the protein…

The Consortium of Multiple Sclerosis Centers (CMSC) has launched a monthly webinar series, in partnership with NeurologyLive, to keep doctors and others treating people with multiple sclerosis (MS) informed of the latest in disease care and research. Called “The Ever Changing Face of MS,” the series opened on…

The Autoimmune Registry (ARI) has opened a fundraiser, called “Cure the Mother’s Disease,” to support the development of a tool that might detect multiple sclerosis (MS) in early stages during an eye exam. This fundraiser, …

Although multiple sclerosis (MS) affects many different races and ethnicities and may even be more aggressive in some of these patient populations, minority representation in MS clinical trials remains critically low. Black patients made up only a fraction of the total enrollment in large-scale Phase 3 trials for three…

The prevalence of fatigue continues to be high among people with multiple sclerosis (MS) despite significant progress over the years in therapies that change the course of the disease, a large survey study in Norway found. The findings also show that the frequency of fatigue is higher in…

A new 3D model of the human nervous system is meant to mimic key processes in the development of the myelin sheath — the fatty coating around nerve cells that is damaged in multiple sclerosis (MS) — to help with research into treatments that promote myelination. This model might also…

Certain fat molecules produced by gut microbes, which have protective immune-suppressing effects and may protect against multiple sclerosis (MS), are lower in women than in men, a case-control study has found. These findings may explain the greater MS susceptibility observed in women, the scientists…

A short film produced for Hispanic/Latinx people who live with multiple sclerosis (MS) improved patients’ understanding of the condition and the effectiveness of treatment, a study found.  “Health communication interventions, like film, have been shown to be effective tools in promoting positive attitudes…

Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive of multiple sclerosis (MS), a condition known as radiologically isolated syndrome. The Phase 4 study (NCT04877457) aims to evaluate whether short-term treatment with Ocrevus can…

The Multiple Sclerosis Society of Canada‘s (MSSC) MS Walk fundraiser is still on for this month — May is MS Awareness Month in Canada — although in an altered form due to the pandemic. The annual nationwide community-driven event raises funds and MS awareness to help battle the neurodegenerative…

Two global Phase 3 clinical trials comparing fenebrutinib, an investigational oral BTK inhibitor by Roche, with Aubagio (teriflunomide) are now enrolling adults with relapsing forms of multiple sclerosis (MS), the National MS Society announced in a press release. The twin studies, called FENhance 1 (NCT04586023)…

Subtle Medical announced the granting of a U.S. patent for its radiology software that uses artificial intelligence to improve the quality of medical imaging, with the potential to reduce the amount of gadolinium, a contrast agent, needed to one-tenth of its usual dose. Gadolinium, a heavy metal, is included in…

Treatment with Zeposia (ozanimod) significantly reduces the risk of relapse, decreases the proportion of patients experiencing a relapse, and has a better safety profile than Aubagio (teriflunomide) for people with relapsing multiple sclerosis (MS), according to an indirect comparison of clinical trial data.

People with relapsing-remitting multiple sclerosis (RRMS) using approved oral disease-modifying therapies generally tolerate the treatments well, with real-world adverse event profiles similar to those seen in clinical trials, an analysis of U.S. data indicates. Results also suggest high adherence to these therapies — meaning patients are usually taking the therapies…